|Basophil activation test (EUROBAT)
||Basophil activation marker selection, CD63 or CD203c, improves sensitivity of basophil activation test depending on the clinical entity in immediate allergic reactions to betalactams.
||Limitations in routine use of the basophil activation test in the diagnosis of immediate hypersensitivity reactions to iodinated contrast media: a case report
||Assessment of homologous phospholipases (Polistes and bee venom PLA2) and hyaluronidases (Pol d 2, Api m 2, Ves v 2b) in patients with bee and yellow jacket venom allergy by basophil activation testing
||Hymenoptera venom allergy: Basophil activation tests (BATs) with whole venom extracts and single components (Api m1, Api m10, Ves v1, Ves v5) in double-sensitized patients
||A novel activation marker in basophils cascade
||Basophils in cancer: Propensity for activation, prognostic value and applying the BAT to monitor for hypersensitivity of novel therapeutics
||Heather J Bax